Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29).

“We have made great progress in recent months in advancing TIL therapy toward commercialization. In April, we dosed the first patient in the pivotal study, Cohort 4 of the innovaTIL-01 melanoma trial, bringing us a step closer to our goal of filing for regulatory approval of lifileucel in 2020,” commented Maria Fardis, Ph.D., MBA, president and chief executive officer of Iovance Biotherapeutics. “We are pleased that three Iovance abstracts submitted to ASCO have been accepted, two of which include data updates from our fully enrolled Cohort 2 of our melanoma program and data from our ongoing LN-145 cervical study being presented for the first time in a medical conference at the 2019 meeting.”

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.